Moreover, specific mutations of KRAS that lead to downstream phosphorylation of extracellular signal-regulated kinase (ERK) were found in hyperdiploid patients [8], suggesting that Ras/MEK/ERK network inhibition could be a good therapeutic target in high-hyperdiploid childhood B-ALL. The gene discussed is KRAS; the disease is acute lymphoblastic leukemia.